Table 2.
Allele | Cases (%) | Ischemic Control (%) | OR | Cases (%) | Hemorrhagic Control (%) | OR | P |
---|---|---|---|---|---|---|---|
APOE | n=23 | n=116 | n=18 | n=116 | |||
ε2ε2 | 0 | 0 | 0.7663 (0.239-2.459) | 0 | 0 | ||
ε2ε3 | 4 (174) | 25 (21.6) | 2.336 (0.557-9.804) | 0 | 25 (21.6) | 0.097 (0.006-1.67) | ≤0.05 |
ε2ε4 | 3 (13.0) | 7(6) | 1.32 (0.524-3.321) | 4 (22.2) | 7(6) | 4.45 (1.15-17.1) | ≤0.05 |
ε3ε3 | 9 (39.1%) | 38 (32.8) | 0.934 (0.354-2.465) | 6 (33.3) | 38 (32.8) | 1.03 (0.358-2.95) | |
ε3ε4 | 7 (30.4) | 37 (31.9) | 0.24 (0.014-4.286) | 7 (38.9) | 37 (31.9) | 1.36 (0.487-3.79) | |
ε4ε4 | 0 | 9 (7.7) | 1.122 (0.462-2.724) | 1 (5.6) | 9 (7.7) | 0.699 (0.083-5.88) | |
ε2 | 7 (15.2) | 32 (13.8) | 1.162 (0.604-2.234) | 4(11.1) | 32 (13.8) | 0.781 (0.259-236) | |
ε3 | 29 (63.0) | 138 (59.5) | 0.762 (0.357-1.627) | 19 (52.8) | 138 (59.5) | 0.761 (0.376-1.54) | |
ε4 | 10 (21.7) | 62 (26.7) | 13 (36.1) | 62 (26.7) | 1.55 (0.740-3.25) | ||
MTHFR | n=23 | n=116 | n=18 | n=116 | |||
CC | 15 (65.2) | 96 (82.8) | 0.39 (0.146-1.045) | 15 (83.3) | 96 (82.8) | 1.04 (0.275-3.94) | |
CT | 8 (34.8) | 20 (17.2) | 2.56 (0.957-6.85) | 3 (16.7) | 20 (17.2) | 0.96 (2.54-3.63) | |
TT | 0 | 0 | 0 | 0 | |||
C | 38 (82.6) | 212 (91.4) | 0.448 (0.184-1.091) | 33 (91.7) | 212 (91.4) | 1.04 (0.292-3.69) | |
T | 8 (17.4) | 20 (8.6) | 2.23 (0.917-5.43) | 3 (8.3) | 20 (8.6) | 0.964 (0.271-3.42) | |
ACE | n=23 | n=116 | n=23 | n=116 | |||
AA (II) | 18 (81.0) | 90 (77.6) | 1.04 (0352-3.07) | 15 (70.0) | 90 (77.6) | 0.542 (0.207-1.42) | |
AG (ID) | 5 (19.0) | 20 (17.2) | 1.33 (0.443-4.01) | 5 (20.0) | 20 (17.2) | 1.33 (0.443-4.01) | |
GG (DD) | 0 | 6(5) | 0.362 (0.0197-6.65) | 3 (10.0) | 6(5) | 2.75(0.635-11.9) | |
A (I) | 41 (90.5) | 200 (86.2) | 1.31 (0.482-3.57) | 35 (80.0) | 200 (86.2) | 0.509 (2.35-1.10) | |
G (D) | 5 (9.5) | 32 (13.8) | 0.762 (0.280-2.07) | 11 (20.0) | 32 (13.8) | 1.96 (0.906-4.26) |